New York, United States, May 24, 2022 (GLOBE NEWSWIRE) -- Platelet-rich plasma (PRP) therapy utilizes the patient's platelets by loading its concentration in the injection to enhance the healing of different body parts like the injured ligaments, tendons, muscles and joints. The PRP injections utilize each patient's own healing system to improvise the various musculoskeletal problems. Based on the Sample type, the ‘Pure PRP’ market segment possessed the largest proportion of the entire Platelet Rich Plasma market, with 52.8% in 2020. It is anticipated to maintain its dominance over 2020-2030. Moreover, based on region, North America dominated the total Platelet Rich Plasma Market with 45.5% in 2020. On the other side, the Asia Pacific region previses to witness the highest CAGR of around 14.1%.
To get a first-hand overview of the report, Request a Sample at
https://www.strategicmarketresearch.com/request-sample/platelet-rich-plasma-market
The segmentation of the latest report published by Strategic Market Research on Platelet Rich Plasma Market is as follows:
Based on the Sample type
- Pure PRP
- Leukocyte-rich PRP
- Pure PRF
Based on the Origin
- Autologous
- Allogenic
- Homologous
Based on Application
- Orthopaedic surgery
- Cosmetic surgery
- General surgery
- Neurosurgery
Regional Analysis
- North America
- Europe
- Asia-Pacific
- LAMEA
Make a Direct Purchase of the latest Platelet Rich Plasma Market Report published in the month of December 2021. Click the below link to initiate the purchase:
https://www.strategicmarketresearch.com/buy-now/platelet-rich-plasma-market
The Market for Global Platelet Rich Plasma is prevised to reach a market value of USD 985 million by 2030 from USD 314 million in 2020, at a CAGR of 12.12 percent throughout the projected period. The increase in the overall usage of platelet-rich plasma to treat anti-ageing problems & removing stretch marks, cure sports injuries, and increase in cosmetic &surgical procedures are the key drivers that amplify the market's overall growth. In 2019, over 18.1 million cosmetic surgeries were carried out in the United States, as per the American Society of Plastic Surgeons (ASPS).
By Sample type, the ‘Pure PRP’ market segment held the greatest share of the Platelet Rich Plasma Market.
Based on the Sample type, the total Platelet Rich Plasma Market has been classified into Pure PRP, Leukocyte-rich PRP and Pure PRF. Among these segments, the ‘Pure PRP’ market segment possessed the largest proportion of the entire platelet Rich Plasmamarket with a share of 52.8% in 2020. It is mainly due to the rise in the technical developments in the PRP devices, which have led to the increase in the overall usage of pure PRP in various situations.In accordance with the National Library of Medicine, the overall platelet count of 10 lakh/ml in 5 mL of PRP, is regarded as a working definition of PRP, based on the scientific proof of bone and soft tissue healing.
By Origin, the ‘Autologous ’ market segment had the largest share of the total Platelet Rich Plasma Market.
Based on the Origin, ‘Autologous’ market segment held the highest Platelet Rich Plasma Market share in 2020. Autologous platelet-rich plasma (PRP) is a straightforward, safe, and cost-effective cure that promotes key parameters like cell migration, proliferation, and angiogenesis. Moreover, autologous PRP is highly effective in the overall treatment of chronic non-healing ulcers. The need for autologous PRP is likely to grow mostly in developed nations worldwide. In accordance with NCBI, chronic non-healing ulcers are an extremely serious public health problem that mostly affects the estimation of around 2–6 million people in the United States alone, with global prevalence ranging from 1.9% to 13.1% of the total population.
By Application, the ‘Orthopaedic surgery market segment dominated the entire Platelet Rich Plasma Market.
Based on the Application, the ‘Orthopaedic surgery; held the maximum proportion of the entire Platelet Rich Plasma market share in 2020. During the projection period, the segment is expected to be driven by the rise in orthopaedic procedures globally. The Orthopedists mostly utilize knee and hip prostheses, which enable the patients to restore the complete range of motion, pain-free, in a very short span of time. As per the Rehabilitation Research and Training Centre on Disability Statistics and Demographics, in the United States, the overall percentage of the population with impairments has surged from roughly 11.9% to 12.9%.
North America possessed the largest share of the entirePlatelet Rich Plasma Market throughout the projected period
Based on Regions, North America dominated the total Platelet Rich Plasma Market with a 45.5% market share in 2020. The rise in the prevalence of numerous ailments, such as arthritis, improved regulatory environment, and well-established healthcare infrastructure accounted for the market's overall expansion, especially in the United States. According to the report published by CDC(Centers for Disease Control and Prevention), approximately 54.4 Million people (i.e. 22.7 %) in the entire United States have been diagnosed with diseases like rheumatoid arthritis, common arthritis, gout, etc. On the other side, the Asia Pacific region is prevised to witness the highest CAGR of around 14.1%.
Before initiating a purchase, make a Pre-order enquiry and get a detailed overview of the content of the report
https://www.strategicmarketresearch.com/pre-order-enquiry/platelet-rich-plasma-market
The topmost players that are covered in the Global Platelet Rich Plasma Market report are:
- SelfDiagnostics
- Quidel Corporation
- F. Hoffmann-La Roche Ltd.
- Dickinson and Company
- Trinity Biotech plc
- Becton
- Bionime Corporation
- Abbott
- ARKRAY, Inc.
- ACON Laboratories, Inc.
- Assure Tech. (Hangzhou) Co., Ltd.
- Zimmer Biomet Holdings Inc.
- Royal Biologics
Kindly go through and get access to our comprehensive coverage of myriad number of healthcare reports published in the last three months:
https://www.strategicmarketresearch.com/reports/healthcare
Global Platelet Rich Plasma Market: Recent Developments
- On 8th September, 2021, the Royal Biologics declared the clearance of FDA 510(k) approval of their Maxx-PRP concentration system. The Maxx-PRP is a patented next-generation concentration product that can be utilized to concentrate the autologous whole blood for the safe and rapid preparation of platelet-rich plasma. The Royal's Maxx-PRP system offers "customizable formulations" of platelet-rich plasma, thus enabling the clinicians to cure a variety of conditions in the fields like sports medicine, plastic surgery, orthopedics, and regenerative medicine.
- On 1st July, 2021, Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, declared their partnership with OSSIS to serve as the exclusive Asia Pacific distributor for its patient-specific 3D printed titanium hip replacement joints. This partnership will enable Zimmer Biomet to offer an extensive network of orthopaedic surgeons with an alternative of patient-specific implants framed with a combination of clinical and engineering expertise.
- On 20th Feb, 2020, EmCyte, the market leader in platelet rich plasma and progenitor stem cell biologics, finalized the acquisition of all the assets of Cellmedix Holdings LLC, involving the Centrepid Platelet Concentrator system. This acquisition will boost the intellectual property profile of EmCyte Corporation and will help in extending its entire product development capabilities.
Related Reports
Global Hemostats and Tissue Sealants Market Report
The vital report on “Hemostats and Tissue Sealants Market” Insights & Forecast 2030 published by Strategic Market Research delivers a 360-degree concept of the various market insights. The market was valued at 6.35 Billion in 2020, and it's anticipated to rise up to 11.27 Billion by 2028 with a promising CAGR of 8.93 %. The various factors that significantly expediting the market growth are the increasing occurrences in adhesion prevention and the rise of applications in drug delivery mechanisms. Some of the leading companies associated with the market are Baxter, Integra Life Sciences Corporation, Advanced Medical Solutions Group plc, B Braun Medical Inc, Cohera Medical Inc, CryoLife Inc, C.R. Bard Inc, Johnson & Johnson Services Inc, Pfizer Inc, Cohesion Technologies Inc, etc.
Global Protein expression Market Report
The vital report on “Protein expression Market” Insights & Forecast 2030 published by Strategic Market Research delivers a crystal clear idea of the key market insights. The market was valued at 2.2 billion in 2020, and it's estimated to increase up to 6.47 billion by 2030 with a decent CAGR of 11.4 %. The increase in the cases of illnesses like cancer and cardiovascular disease, the rise in genetic disorders and the growing investments by the leading manufacturers in the protein expression systems are the most significant drivers of this market. The key players in the Global Protein expression Marketare Agilent Technologies Inc. Merck KGaA Takara Bio Inc New England Biolabs BECTON, DICKINSON AND COMPANY BIO-RAD LABORATORIES, INC. GenScript Biotech Corporation LifeSensors Inc. Promega Corporation QIAGEN NV. THERMO FISHER SCIENTIFIC, INC. Oxford Expression Technologies Ltd. Synthetic Genomics Inc.
Global Hormone Replacement Therapy Market Report
The vital report on “Hormone Replacement Therapy Market” Insights & Forecast 2030 published by Strategic Market Research elucidates a concrete understanding of the pivotal market insights. The market was valued at 23.156 billion in 2020, and it's expected to rise up to a benchmark of 39.631 billion by 2028 with a robust CAGR of 7.83%. The surge in the prevalence of menopausal illness, the rising awareness of post-menopausal difficulties among women, and the rising incidence rate of hormonal abnormalities in adults, newborns, and the elderly are some of the most significant factors fueling the growth of the market. The most dominant players operating in the market are Abbott Laboratories, Bayer Ag.Eli Lily And Company, Pfizer Inc., Hisamitsu Pharmaceutical Co., Hoffmann-La Roche Ltd. (Genentech, Inc.), Inc. (Noven Pharmaceuticals, Inc.), Merck Kgaa, Mylan N.V. (Viatris Inc.), Novartis International Ag, Novo Nordisk A/S.
Global Multiplex Assays Market Report
The vital report on “Multiplex Assays Market” Insights & Forecast 2030 published by Strategic Market Research asserts a concrete understanding of pivotal market insights. The market was valued at 3.13 billion in 2020, and it's assumed to grow up to 6.47 billion by 2030 with a decent CAGR of 7.53%. The perpetual rising of chronic (non-communicable) and infectious diseases throughout the globe, the increase in the awareness of disease diagnosis, the growing prevalence of multiplex assays in companion diagnostics, and the rise in the requirement for effective analytical platforms in research and development are the key amplifiers that are expediting the overall growth of the market. The key players in the global market are Luminex Corporation, Illumina Inc, Bio-Rad Laboratories, Inc, Qiagen N.V., Thermo Fisher Scientific Inc, Abcam plc, Merck KGaA, Agilent Technologies, Inc, Becton, Dickinson and Company, Meso Scale Diagnostics, Randox Laboratories, Quanterix, Bio-Techne Corporation, Olink, DiaSorin S.p.A., Seegene, Promega Corporation, Siemens Healthineers, PerkinElmer Inc, Shimadzu Biotech, Antigenix America, Inc, Enzo Life Sciences, Inc, Boster Biological Technology, AYOXXA Biosystems GmbH, and Cayman Chemical Company.
Global Live-cell imaging Market Report
The vital report on “Live-cell imaging Market” Insights & Forecast 2030 published by Strategic Market Research delineates a concrete understanding of the key market insights. The market was valued at 1.8 Billion in 2020, and it's predicted to reach up to 4.18 Billion by 2030 with a CAGR of 8.8%. The growing demand for various live-cell imaging technologies and the high mortality rate associated with CVDs are the significant drivers of the Live Cell Imaging Market. The major players operating in the Global Live cell imaging market are Danaher Corporation, Carl Zeiss AG, Nikon Corporation, Olympus Corporation, PerkinElmer, Inc., G.E. Healthcare, Bruker Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Oxford Instruments, BioTek Instruments, Etaluma Inc., CytoSMART Technologies, NanoEnTek Inc., Phase Focus Limited, Tomocube Inc., Phase Holographic Imaging PHI AB, B.D. Biosciences, Sony Biotechnology Inc., Merck KGaA, KEYENCE Corporation, ibidi GmbH, Bio-Rad Laboratories, Logos Biosystems, and Nanolive SA.
About Us:
Strategic Market Research facilitates the organizations globally in taking pivotal business decisions by furnishing the Syndicated and Customized Research Reports, which are highly precise in terms of market numbers. We believe that every firm, whether it is a startup which is in the Introduction stage of the Product Life cycle or an established one which is at the growth stage, requires market research services in order to streamline its key business blueprint. It may be related to Product Launch, Go to Market strategies, Competitive Analysis or new geographical penetration and expansion.
Contact Us:
Strategic Market Research LLP.
Sunil Kumar
US: +1-8317045538
UK: +441256636046
India: +91-8260836500
Email: info@strategicmarketresearch.com
Web: https://www.strategicmarketresearch.com
Blog: https://www.strategicmarketresearch.com/blog
Press Release: https://www.strategicmarketresearch.com/press-releases
Connect Us:
LinkedIn: https://www.linkedin.com/company/strategic-market-research/
Twitter: https://twitter.com/smrstrategic
Facebook: https://www.facebook.com/StrategicMarketResearch
Instagram: https://www.instagram.com/strategicmarketresearchsmr/
